Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Abrams

Showing results (351-360 of 367) with videos related to

Pageof 37
Sort By:
Oncogene|March 12, 2008
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitorsL S Steelman, P M Navolanic, M L Sokolosky, et al.
Journal of Molecular Medicine (Berlin, Germany)|March 9, 2012
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategiesMaria Rosaria Ricciardi, Maria Cristina Scerpa, Paola Bergamo, et al.
Oncotarget|September 26, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy responseJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Aging|June 15, 2017
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAsJames A McCubrey, Kvin Lertpiriyapong, Linda S Steelman, et al.
Oncotarget|October 23, 2012
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Advances in Biological Regulation|November 6, 2019
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cellsShaw M Akula, Saverio Candido, Stephen L Abrams, et al.
Advances in Biological Regulation|May 4, 2019
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cellsShaw M Akula, Saverio Candido, Massimo Libra, et al.
Aging|March 23, 2011
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S Steelman, William H Chappell, Stephen L Abrams, et al.
Advances in Biological Regulation|March 23, 2019
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticalsSaverio Candido, Stephen L Abrams, Linda S Steelman, et al.
Oncotarget|March 18, 2011
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human healthWilliam H Chappell, Linda S Steelman, Jacquelyn M Long, et al.
Pageof 37

Showing results (351-360 of 367) with videos related to

Sort By:
Pageof 37
Oncogene|March 12, 2008
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitorsL S Steelman, P M Navolanic, M L Sokolosky, et al.
Journal of Molecular Medicine (Berlin, Germany)|March 9, 2012
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategiesMaria Rosaria Ricciardi, Maria Cristina Scerpa, Paola Bergamo, et al.
Oncotarget|September 26, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy responseJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Aging|June 15, 2017
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAsJames A McCubrey, Kvin Lertpiriyapong, Linda S Steelman, et al.
Oncotarget|October 23, 2012
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Advances in Biological Regulation|November 6, 2019
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cellsShaw M Akula, Saverio Candido, Stephen L Abrams, et al.
Advances in Biological Regulation|May 4, 2019
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cellsShaw M Akula, Saverio Candido, Massimo Libra, et al.
Aging|March 23, 2011
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S Steelman, William H Chappell, Stephen L Abrams, et al.
Advances in Biological Regulation|March 23, 2019
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticalsSaverio Candido, Stephen L Abrams, Linda S Steelman, et al.
Oncotarget|March 18, 2011
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human healthWilliam H Chappell, Linda S Steelman, Jacquelyn M Long, et al.
Pageof 37